Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
3 reports, 2 independent
Updated Sep 8
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Also in this story
- Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.
- Eli Lilly acquired Verve Therapeutics, advancing one-time treatments for high cardiovascular risk.
- Mineralys Therapeutics presented its clinical trial results at the American Heart Association sessions in Baltimore.
- Novartis gains exclusive rights to develop ARO-SNCA through a collaboration that validates Arrowhead's TRiM technology.
The entities involved
-
Ionis Pharmaceuticals
American pharmaceutical company
-
Novartis
Swiss-American multinational pharmaceutical corporation
Related events
- Novartis announced that the Lp(a)HORIZON clinical trial failed to meet its primary endpoint on September 1, 2026.
- Ionis Pharmaceuticals' RNA drug failed a study, while Eli Lilly invested in a spinout from Kura Oncology.
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- Ionis Pharmaceuticals is seeking FDA approval for its treatments for Alexander disease, including Tryngolza, and has formed new partnerships with AstraZeneca and Hoffmann-La Roche.
- Novartis and Novo Nordisk experienced simultaneous major drug program failures on September 14, 2026.